Abstract
IntroductionFor patients with cancer, immune checkpoint inhibitors (ICIs) produce superior long-term responses compared with alternative treatments, although at the cost of manifesting adverse immune-related events. There are many hypotheses of...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have